{
  "docId": "019de075-4481-714f-9573-a4ad96e0f148",
  "docSlug": "816ee2fbc8fb2bf52edc4f2891aaa98f",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 27 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 17,
  "pageCount": 27,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide uses a funnel-like diagram to represent the patient recruitment and study flow.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4481-714f-9573-a4ad96e0f148/17",
  "deckHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148",
  "deckJsonHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148.json",
  "deckAnchorHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.08,
        "y": 0.265
      },
      "kind": "diagram",
      "text": "Over 10,000 women applied to enroll in the study -> Patient Screening -> Patient Enrollment -> No Drug Run In (4 Weeks) -> Single Blind Run-In (4 Weeks) -> Randomization (Double-blind, 12 weeks) -> Active / Placebo",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b2b4470-6e54-4ba1-870d-663571a0502a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.08,
        "y": 0.46
      },
      "kind": "list",
      "text": "Thousands of women completed the online form expressing interest in the study\nPatient screening included phone, medical history and exam, and centralized clinical interview screens to fully characterize symptoms and co-morbidities\nPartners were enrolled in the study for safety data capture\nSubjects completed both electronic diary assessments post sexual events as well as 28-day recall questionnaires (every 4 weeks)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2dd79d18-e093-4d2f-bf5f-94cc5dca3613",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6% – Phase 2b RESPOND Study – Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc91992f-2ece-4ab4-bfaf-b809e8d33416",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "2c7cd2b2-9f67-4a33-b814-58683e7ee2d2",
      "evidence": "The slide depicts a sequential clinical trial workflow.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}